...
首页> 外文期刊>Neurotherapeutics >Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury
【24h】

Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury

机译:用于脑外伤的诊断,预后和疗效评估的生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Traumatic brain injury (TBI) remains a serious health concern, and TBI is one of the leading causes of death and disability, especially among young adults. Although preventive education, increased usage of safety devices, and TBI management have dramatically increased the potential for surviving a brain injury, there is still a need to develop reliable methods to diagnose TBI, the secondary pathologies associated with TBI, and predicting the outcomes of TBI. Biomarkers (changes of amount or activity in a biomolecule that reflect injury or disease) have shown promise in the diagnosis of several conditions, including cancer, heart failure, infection, and genetic disorders. A variety of proteins, small molecules, and lipid products have been proposed as potential biomarkers of brain damage from TBI. Although some of these changes have been reported to correlate with mortality and outcome, further research is required to identify prognostic biomarkers. This need is punctuated in mild injuries that cannot be readily detected using current techniques, as well as in defining patient risk for developing TBI-associated secondary injuries.
机译:颅脑外伤(TBI)仍然是严重的健康问题,TBI是导致死亡和残疾的主要原因之一,尤其是在年轻人中。尽管进行了预防性教育,增加了安全设备的使用以及TBI管理大大增加了幸存者患脑损伤的可能性,但仍需要开发可靠的方法来诊断TBI,与TBI相关的继发性病理并预测TBI的结果。生物标志物(反映损伤或疾病的生物分子中数量或活性的变化)已在诊断包括癌症,心力衰竭,感染和遗传疾病在内的多种疾病中显示出希望。已经提出了多种蛋白质,小分子和脂质产物作为TBI对脑损伤的潜在生物标记。尽管已经报道了其中一些变化与死亡率和结果相关,但仍需要进一步的研究以鉴定预后的生物标志物。轻度伤害是当前技术无法轻易发现的轻伤,并且在确定患者发生与TBI相关的继发性伤害的风险时,这种需求也被迫中断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号